Media stories about Mast Therapeutics (NYSE:MSTX) have been trending positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mast Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 43.9496290330437 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Mast Therapeutics (NYSE:MSTX) traded down 5.278% during trading on Friday, reaching $0.131. 15,259,475 shares of the company were exchanged. The firm’s 50 day moving average is $0.12 and its 200 day moving average is $0.11. Mast Therapeutics has a 1-year low of $0.07 and a 1-year high of $0.71.

ILLEGAL ACTIVITY WARNING: “Mast Therapeutics (MSTX) Earning Favorable Media Coverage, Report Shows” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at

Mast Therapeutics Company Profile

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.